Clinical management of prolactinomas: A ten-year experience
- 22 Downloads
A ten-year experience on 36 patients bearing macroprolactinomas (MP) and 86 others bearing microprolactinomas (mP) is reported in this study. Different therapeutical approaches were used: 1) trans-sphenoidal surgery in 24 patients with MP and in 25 with mP; 2) medical therapy with the oral form of bromocriptine (BRC) in all the 24 patients with MP previously subjected to surgery, in 48 patients with mPab initio, and in 16 out of 25 patients with mP previously subjected to surgery; 3) medical therapy with the long-acting injectable forms of BRC in 12 MP-and 13 mP-bearing patients, and 4) conventional radiotherapy in 12 of the 24 patients with MP previously subjected to surgery. The follow-up, performed five years after surgery, showed that: a) all the 24 patients with MP but one had normal PRL levels during BRC administration, with a rebound of hyperprolactinemia in all cases after withdrawal; b) during the treatment BRC caused normalization of PRL in 15 of the 16 mP-bearing patients surgically treated and in all the 48 mP-bearing patients only treated with BRC; c) in 20 of the 25 patients the treatment with injectable retard BRC caused the normalization of plasma PRL and the shrinkage of the tumor mass in all the patients with MP but one, as revealed by seriate CT scans. In conclusion, the surgical treatment of prolactinomas was ineffective to normalize plasma PRL levels in most patients whereas BRC, in standard or in retard forms, was able to normalize plasma PRL levels, reduce the tumoral mass and preserve the pituitary residual tissue. BRC should be, therefore, used as first choice therapy both for MP and mP.
Key WordsProlactinomas Transsphenoidal Surgery Radiotherapy Bromocriptine
Unable to display preview. Download preview PDF.
- 2.Reichlin S: The prolactinoma problem.N Eng J Med 300, 313 (1979).Google Scholar
- 3.Fahlbusch R: Surgical failures in prolactinornas, in: Derome P J, Jedynak C P, Peillon F (eds):Pituitary Adenomas, pp. 273–284. Asciepios, Paris (1980).Google Scholar
- 7.Molitch M E, Elton R L, Blackwell R E, Caldwell B, Chang R J, Jaffe R, Joplin G, Robbins R J, Tyson J, Thorner M O and the Bromocriptine Study Group: Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicentric study.J Clin Endocrinol Metab 60, 698 (1985).PubMedGoogle Scholar
- 11.Hardy J: Ten years after recognition of pituitary microadenoma, in: Faglia G, Giovannelli M A and MacLeod R M (eds):Pituitary micro adenomas, pp. 7–14. Academic Press, London (1980).Google Scholar
- 12.Derome P J, Peillon F, Bard R H, Jedynak C P, Racadot J, Guiot G: Adenomes à prolactine: resultats du traitment chirurgical. 120 cas feminins 30 cas masculins.Nouv Press Med 8, 577 (1979).Google Scholar
- 13.Post K D: Surgical approaches to the treatment of prolactinomas, in: Olefsky J M and Robbind R J (eds):Prolactinomas. Contemporary issue in Endocrinology and Metabolism, pp. 159–194. Churchill Livingstone, New York (1986).Google Scholar
- 14.Vance M L, Thonier M O: Prolactinomas, in: Molitch ME (ed):Pituitary Tumors: Diagnosis and Management. Endocrinology and Metabolism Clinics, pp.731–753. WB Saunders Company, London (1987)Google Scholar
- 15.de Divitiis E, Spaziante R: The actual role of surgery in the treatment of PRL-secreting pituitary adenomas, in: Gennazzani A R, Montemagno U, Nappi C and Petraglia F (eds):Brain and Female Reproductive Function, pp. 539–551. The Parthenon Publishing, Carnforth (1987).Google Scholar
- 16.Schettini G, Lombardi G, Merola B, Colao A, Miletto P, Caruso E, Lancranjan I: Rapid and long-lasting suppression of prolactin secretion and shrinkage of prolactinomas after injection of long-acting repeatable form of bromocriptine (Parlodel LAR).Clin Endocrinol 33, 161 (1990).CrossRefGoogle Scholar